Abstract
In the past decade, the therapeutic potential of arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL) was recognized. This encouraged other investigators to test the efficacy of ATO in the management of other hematological and solid tumor malignancies. Notably, as a single agent, arsenic trioxide did not benefit patients diagnosed with solid tumors. However, when it was combined with other agents, treatment benefit emerged. In this article, we have summarized the outcome of clinical trials that used arsenic trioxide as a single agent as well as in combination settings in patients diagnosed with solid tumors. We have also reviewed possible additional mechanisms by which ATO may be useful as a chemosensitizer in combination therapy. We hope that our review will encourage clinical investigators to rationally combine ATO with additional chemotherapeutic agents in treating patients diagnosed with solid tumors.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 363-371 |
| Number of pages | 9 |
| Journal | Journal of Gastrointestinal Cancer |
| Volume | 45 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 1 2014 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Gastroenterology
Cite this
In the war against solid tumors arsenic trioxide needs partners. / Pochi, Subbayan; Ardalan, Bach.
In: Journal of Gastrointestinal Cancer, Vol. 45, No. 3, 01.09.2014, p. 363-371.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - In the war against solid tumors arsenic trioxide needs partners
AU - Pochi, Subbayan
AU - Ardalan, Bach
PY - 2014/9/1
Y1 - 2014/9/1
N2 - In the past decade, the therapeutic potential of arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL) was recognized. This encouraged other investigators to test the efficacy of ATO in the management of other hematological and solid tumor malignancies. Notably, as a single agent, arsenic trioxide did not benefit patients diagnosed with solid tumors. However, when it was combined with other agents, treatment benefit emerged. In this article, we have summarized the outcome of clinical trials that used arsenic trioxide as a single agent as well as in combination settings in patients diagnosed with solid tumors. We have also reviewed possible additional mechanisms by which ATO may be useful as a chemosensitizer in combination therapy. We hope that our review will encourage clinical investigators to rationally combine ATO with additional chemotherapeutic agents in treating patients diagnosed with solid tumors.
AB - In the past decade, the therapeutic potential of arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL) was recognized. This encouraged other investigators to test the efficacy of ATO in the management of other hematological and solid tumor malignancies. Notably, as a single agent, arsenic trioxide did not benefit patients diagnosed with solid tumors. However, when it was combined with other agents, treatment benefit emerged. In this article, we have summarized the outcome of clinical trials that used arsenic trioxide as a single agent as well as in combination settings in patients diagnosed with solid tumors. We have also reviewed possible additional mechanisms by which ATO may be useful as a chemosensitizer in combination therapy. We hope that our review will encourage clinical investigators to rationally combine ATO with additional chemotherapeutic agents in treating patients diagnosed with solid tumors.
UR - http://www.scopus.com/inward/record.url?scp=85027923556&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027923556&partnerID=8YFLogxK
U2 - 10.1007/s12029-014-9617-8
DO - 10.1007/s12029-014-9617-8
M3 - Review article
C2 - 24825822
AN - SCOPUS:85027923556
VL - 45
SP - 363
EP - 371
JO - Journal of Gastrointestinal Cancer
JF - Journal of Gastrointestinal Cancer
SN - 1941-6628
IS - 3
ER -